Amedisys (NASDAQ:AMED) initiated with Market Perform rating and $170 (3% upside) price target at BMO.
Athenex (NASDAQ:ATNX) initiated with Buy rating and $28 (70% upside) price target at SunTrust.
Gossamer Bio (NASDAQ:GOSS) initiated with Overweight rating and $34 (38% upside) price target at Cantor Fitzgerald.
Odonate Therapeutics (NASDAQ:ODT) initiated with Sell rating and $26 (22% downside risk) price target at Goldman Sachs.
Puma Biotechnology (NASDAQ:PBYI) initiated with Buy rating and $15 (102% upside) price target at H.C. Wainwright. Shares up 6% premarket.
Sierra Oncology (NASDAQ:SRRA) initiated with Outperform rating and $1.20 (213% upside) price target at Oppenheimer. Shares up 30% premarket.
Epizyme (NASDAQ:EPZM) upgraded to Overweight with a $22 (44% upside) price target at Morgan Stanley.
HCA Healthcare (NYSE:HCA) upgraded to Buy with a $160 (14% upside) price target at BofA Merrill Lynch.
Sage Therapeutics (NASDAQ:SAGE) upgraded to Market Perform at SVB Leerink. Shares up 2% premarket.
Anthem (NYSE:ANTM) downgraded to Neutral with a $330 (15% upside) price target at BofAML.
Teladoc (NYSE:TDOC) downgraded to Hold with an $80 (1% upside) price target at Jefferies. Shares down 2% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.